Nachrichten zur Eli Lilly & Co. Aktie

Eli Lillys Wegovy rival Mounjaro gets UK green light

Mounjaro, Eli Lillys (NYSE:LLY) rival weightloss drug to Wegovy and Ozempic, is to be made available in the UK after receiving…

Pharma’s Weight-Loss Bonanza

The success of Ozempic and Wegovy has turned Novo Nordisk into Europe’s biggest company. But Eli Lilly’s newest version of…

Eli Lilly gene therapy restores hearing in Phase 1/2 trial

…

Stock Of The Day Lilly Is In A Buy Zone. And Its Not Tied To Obesity.

An Eli Lilly subsidiary thinks it might have the solution to a genetic form of hearing loss.…

Eli Lillys Zepbound is off to a strong start, but heres what needs to happen to push shares higher

Investors will be tuning into the companys fourth quarter earnings call on Feb. 6, eager to hear more about how…

Eli Lilly gene therapy allows child born deaf to hear, clinical trial shows

…

Cramer taps Eli Lilly as a new member of the Magnificent Seven if Tesla earnings falter

CNBCs Jim Cramer said Tesla may have hit a "growth pause," compared to its Big Tech peers that are still…

Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors

The addition of UCB’s Bimzelx in the EU and pending US approval adds to the growing momentum of the class,…

LEXX’ Sweet Opportunity in GLP-1s

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Following the rollover into the new year, Lexaria Bioscience Corporation (NASDAQ:LEXX) updated…

Pro Research: Wall Street digs into Eli Lillys robust outlook By Investing.com

Pro Research: Wall Street digs into Eli Lillys robust outlook…

Is It Too Late to Buy Eli Lilly Stock?

Eli Lilly is now the most valuable healthcare stock in the world.…

Is It Too Late to Buy Eli Lilly Stock? @themotleyfool #stocks $LLY

Eli Lilly is now the most valuable healthcare stock in the world.…

The S&P 500 set a new record high. How our current Club stocks have fared since the last one

The S&P 500 notched a record close Friday for the first time in more than two years — and over…

Will Eli Lilly Be Worth More Than Meta Platforms by 2030?

It would be quite the accomplishment for the drugmaker.…

Eli Lilly: The Cupboard Is Fully Stocked

…

Exclusive-US FDA finds new manufacturing lapses at Eli Lilly plant By Reuters

Exclusive-US FDA finds new manufacturing lapses at Eli Lilly plant…

FDA finds new manufacturing lapses at Eli Lilly plant

U.S. inspectors recently uncovered new manufacturing problems at an Eli Lilly plant that has been under scrutiny by federal investigators.…

Goldman Sachs zuversichtlich: Studie vergleicht Eli Lilly mit Apple oder Amazon

Der Wachstumsmarkt rund um die sogenannte Abnehmspritze sorgte 2023 bei den führenden Unternehmen Eli Lilly und Novo Nordisk für massive…

Why Eli Lilly Stock Tumbled on Thursday

Investors were a bit concerned about an industrywide move.…

Top Analyst Reports for Eli Lilly, Linde & NextEra Energy

Todays Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Linde plc (LIN)…

The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space

Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss…

Top 5 Life Science ETFs

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the…

ADDvise receives order worth EUR 2.1 million

ADDvise Group’s subsidiary Labplan has received an order from the pharmaceutical company Eli Lilly. The order is worth approximately EUR 2.1…

These 2 Top Healthcare Stocks Declared Dividend Raises in 2023

For different reasons, both Eli Lilly and UnitedHealth are doing well enough to enact substantial dividend raises.…

These 2 Top Healthcare Stocks Declared Dividend Raises in 2023 @themotleyfool #stocks $LLY $NVO $UNH

For different reasons, both Eli Lilly and UnitedHealth are doing well enough to enact substantial dividend raises.…

The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca

Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.…

Move Over, Novo Nordisk -- This Is the Pharmaceutical Company I am Most Bullish On in 2024

Novo Nordisk may dominate the weight management space, but pharma giant Eli Lilly is quickly gaining steam.…

Two Health Care Leaders Scale New Highs On Big Wins

Eli Lilly is moving as LLY stock is at an all time high. Stryker stock is also at an all-time…

Whats old is new: Our 3 best stocks to start 2024 were also big winners last year

Nvidia, Eli Lilly and Palo Alto Networks — all top performers last year — are leading the portfolio in the…

Eli Lilly: The Buzz Is Not Over

…

Eli Lillys plans for growth push stock to another new high — plus two more health stock updates

Eli Lilly has no plans to ease up on R&D spending. Meanwhile, Danaher continues to await an inflection point, while…

Eli Lilly Could Be the Next Apple Stock. It Still Looks Cheap.

…

50 Companies to Watch in 2024

From Alphabet and BYD to Eli Lilly and Vivendi, keep an eye on these global stocks this year.…

Eli Lillys direct drug sales may not upend the industry alone – but others could follow suit

LillyDirect is the latest attempt to simplify what critics call a complex system for distributing, pricing and prescribing prescription drugs.…

Pharma Stock Roundup: LLYs New Digital Pharmacy, NVO & ABBVs Fresh R&D Deals

Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two…

Lilly (LLY) Starts Website to Help Access Tirzepatide Drugs

Eli Lillys (LLY) digital pharmacy is expected to provide patients easy access to its FDA-approved tirzepatide medicines, Mounjaro and Zepbound.…

Why WW International Stock Just Dropped 11%

WWs revenue was sliding even before Ozempic came on the scene. Now Eli Lilly has a new weight loss drug…

Eli Lilly aims for a new high after launching DTC service for weight-loss drugs. Cramer says let it ride

The latest catalyst for Eli Lilly is a corporate decision more common in the retail and entertainment industries, not pharmaceuticals.…

Eli Lilly to offer obesity drugs online; hurts Weight Watchers, LifeMD

…

Stocks making the biggest moves midday: Apple, Walgreens, Mobileye, Eli Lilly and more

These are the stocks posting the largest moves in midday trading.…

Eli Lilly stock climbs in 2024 on weight-loss drug outlook

Eli Lilly and Co (NYSE:LLY) shares have gained more than 8% during the past five trading sessions on investor enthusiasm…

Eli Lilly says obesity drugs not for cosmetic use amid digital-sales push

Eli Lilly is looking to deliver its anti-obesity treatments directly to consumers while warning against their use for cosmetic weight…

Eli Lilly launches digital health services for patients with obesity, migraine and diabetes

…

Eli Lilly launches website to help patients get weight loss drugs

The platform, called LillyDirect, joins a growing field of websites offering telehealth prescriptions for weight loss drugs.…

Eli Lilly stock rally extends as BofA names it top biopharma pick for 2024 By Investing.com

Eli Lilly stock rally extends as BofA names it top biopharma pick for 2024…

Everyone Is Talking About Eli Lilly. Is It a Good Long-Term Option?

Eli Lilly shares advanced in the double digits last year.…

Everyone Is Talking About Eli Lilly. Is It a Good Long-Term Option? @themotleyfool #stocks $LLY

Eli Lilly shares advanced in the double digits last year.…

Market Losses Widen; Why Teslas Slide May Be Bullish

The Nasdaq extended a losing streak while Bitcoin retreated. Eli Lilly was a winner again.…

Kursgewinne für das Wertpapier von Eli Lilly (564,5380 €)

Im Plus liegt gegenwärtig die Eli Lilly-Aktie . Zuletzt zahlten Investoren für das Wertpapier 616,69 US-Dollar. Die Eli Lilly-Aktie verzeichnet…

Missed Out on Eli Lilly? My Best Pharmaceutical Stock to Buy And Hold

The past three years were bliss for Eli Lilly shareholders, but those not already on board should look at its…